Back to top
more

AC Immune (ACIU)

(Real Time Quote from BATS)

$2.32 USD

2.32
143,132

+0.20 (9.43%)

Updated Aug 4, 2025 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AMAG Pharmaceuticals' (AMAG) Q2 Loss Narrower Than Expected

by Zacks Equity Research

AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.

Zacks Equity Research

All You Need to Know About AC Immune (ACIU) Rating Upgrade to Strong Buy

by Zacks Equity Research

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales

by Zacks Equity Research

Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.

Zacks Equity Research

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.

Zacks Equity Research

AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study

by Zacks Equity Research

AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.

Zacks Equity Research

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Company News for Mar 24, 2020

by Zacks Equity Research

Companies in the news are: HAS, PCG, WTRH, ACIU

Zacks Equity Research

Moderna (MRNA) Catches Eye: Stock Jumps 6.4%

by Zacks Equity Research

Moderna (MRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

Guardant Health (GH) in Focus: Stock Moves 6.5% Higher

by Zacks Equity Research

Guardant Health (GH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for January 30th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 30th.

Kinjel Shah headshot

5 Biotech Stocks Set to Beat Q3 Earnings Estimates

by Kinjel Shah

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

Zacks Equity Research

Linde (LIN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Favorable industrial production in the United States is likely to have favored Linde's (LIN) Q3 earnings.

Zacks Equity Research

AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AC Immune to Earn Milestone From Lilly for Alzheimer's Drug

by Zacks Equity Research

AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.

Kinjel Shah headshot

6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day

by Kinjel Shah

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.

Zacks Equity Research

Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AC Immune Initiates Phase I Study for Alzheimer's Disease

by Zacks Equity Research

AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.

Zacks Equity Research

AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003

by Zacks Equity Research

Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.

Zacks Equity Research

Lilly (LLY) Signs New Immunology Deal With Private Biotech

by Zacks Equity Research

Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.

Zacks Equity Research

What Makes AC Immune (ACIU) a New Buy Stock

by Zacks Equity Research

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?

by Zacks Equity Research

Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.

Zacks Equity Research

Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?

by Zacks Equity Research

An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.